Stefanie Renken presenting “Clinical Manufacturing of Gene-Modified NK Cells for Allogeneic Therapy”
Stefanie Renken from Vecura presented her talk, “Clinical Manufacturing of Gene-Modified NK Cells for Allogeneic Therapy,” at a full day conference organized by Flemingsberg Science in Campus Huddinge.
Stefanie Renken's presentation gave a comprehensive overview of process development for an ATMP product, from small-scale research to large-scale clinical manufacturing, based on her work in Evren Alici research group at Karolinska Institutet.
Beyond manufacturing workflows, the presentation provided valuable insights into NK cell biology, highlighting key differences compared to T cells, as well as the advantages and challenges of allogeneic versus autologous approaches. Stefanie also emphasized important aspects of GMP production, including collaboration with Vecura GMP facility and the critical infrastructure and knowledge required for successful clinical translation.